CORONA Remedies valuation

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026
Price multiples — at each FY-end close
67.62×—
18.02×—
9.10×—
243.20×—
Enterprise multiples
9.19×—
42.93×—
49.53×—
Yield
1.5%—
0.4%—
Reference — adjusted share basis
₹2,200.60—
₹32.54₹30.27
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

CORONA₹2,200.60

CORONA Remedies Ltd.

· Pharma & Health
₹ CrorePeersERISMANKINDAPLLTDALIVUSAKUMSAGARWALEYEHCGADVENZYMESMcap ₹13,459 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
Multiples — ₹ Crore base
12 Months Ending
FY26
31/03/2026
Current/LTM
TTM · last close
Price Multiples — at each FY-end close
P/E—67.62
P/B—18.02
P/Sales—9.10
Price to Free Cash Flow—243.20
Enterprise Multiples
EV/Sales—9.19
EV/EBITDA—42.93
EV/EBIT—49.53
Yield
Earnings Yield %—1.48
FCF Yield %—0.41
Reference — adjusted share basis
Price (FY-end close, adj.)—2,200.60
EPS (adj.)30.2732.54
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.